Patents by Inventor Reid M. Rubsamen

Reid M. Rubsamen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7028686
    Abstract: Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: April 18, 2006
    Assignee: Aradigm Corporation
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
  • Patent number: 7021309
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: April 4, 2006
    Assignee: Aradigm Corporation
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
  • Publication number: 20040208829
    Abstract: Methods are provided for increasing libido and/or treating erectile dysfunction in a man. The methods include the administration of a formulation testosterone alone, another fast-acting drug to treat erectile dysfunction or a combination of the testosterone and the other drug where at least one is delivered by aersolization. The formulation is preferably aerosolized and inhaled into a patient's lungs where particles of testosterone and/or the fast-acting erectile dysfunction drug deposits on lung tissue and then enter the patient's circulatory system.
    Type: Application
    Filed: October 14, 2003
    Publication date: October 21, 2004
    Applicant: Aradigm Corporation
    Inventors: Reid M. Rubsamen, Robert Cole, James Blanchard, Jeffrey Schuster, Lawrence Linn, John Thipphawong
  • Publication number: 20040182383
    Abstract: The need for the-delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile are improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Application
    Filed: January 30, 2004
    Publication date: September 23, 2004
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
  • Publication number: 20040142013
    Abstract: Surgical devices and methods of treatment using the devices are disclosed. The devices comprise a solid component such as a surgical screw with indentations formed in its surface and spherical particles bound to the indentation. The particles are designed to provide controlled release of antimicrobial compound thereby treating osteomyelitis.
    Type: Application
    Filed: July 10, 2003
    Publication date: July 22, 2004
    Applicant: Flow Focusing, Inc.
    Inventor: Reid M. Rubsamen
  • Publication number: 20040089290
    Abstract: Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.
    Type: Application
    Filed: November 4, 2003
    Publication date: May 13, 2004
    Applicant: Aradigm Corporation
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
  • Publication number: 20040062722
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Application
    Filed: October 8, 2003
    Publication date: April 1, 2004
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
  • Patent number: 6688304
    Abstract: Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: February 10, 2004
    Assignee: Aradigm Corporation
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
  • Patent number: 6647987
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by a method whereby an aerosolized insulin formulation is delivered to a patient's lungs and the rate at which the insulin is absorbed into the blood is increased by the use of an inhale-exhale breathing maneuver. Particles of insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The rate of absorption is enhanced by instructing the patient to inhale maximally and thereafter exhale maximally. The insulin is delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release. The sensor can also assist the patient in the inhale-exhale maneuver.
    Type: Grant
    Filed: June 18, 2002
    Date of Patent: November 18, 2003
    Assignee: Aradigm Corporation
    Inventors: Igor Gonda, Reid M. Rubsamen
  • Patent number: 6632419
    Abstract: The libido of adult human female patients is increased by the bolus delivery of a testosterone which is preferably dihydrotestosterone. The formulation is preferably aerosolized and inhaled into a patient's lungs where particles of testosterone deposits on lung tissue and then enter the patient's circulatory system. The patient's testosterone level is quickly enhanced well above baseline levels for a short period and subsides to baseline levels with normal metabolism thereby providing desired short term effects on enhanced libido without undesirable effects of long term enhanced testosterone levels. Additional formulations are provided including formulations for aerosolized delivery of sildenafil citrate which are delivered to male or female patients.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: October 14, 2003
    Assignees: Aradigm Corporation
    Inventors: Reid M. Rubsamen, Robert Cole
  • Publication number: 20030055075
    Abstract: Controlled release formulations of drugs such as fentanyl and sufentanil are disclosed. The formulations are comprised of two or more different groups of particles wherein the particles of a given group are substantially identical but are different from the particles in any other group. The combined effect of the groups provides steady state blood levels which are particularly useful when administering opioids compound such as fentanyl by injection. A method of reducing unwanted diversion of narcotics is also disclosed.
    Type: Application
    Filed: July 12, 2002
    Publication date: March 20, 2003
    Inventor: Reid M. Rubsamen
  • Publication number: 20030000519
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Application
    Filed: August 5, 2002
    Publication date: January 2, 2003
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
  • Publication number: 20020157677
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by a method whereby an aerosolized insulin formulation is delivered to a patient's lungs and the rate at which the insulin is absorbed into the blood is increased by the use of an inhale-exhale breathing maneuver. Particles of insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The rate of absorption is enhanced by instructing the patient to inhale maximally and thereafter exhale maximally. This maneuver causes a spike in the rate at which insulin enters the circulatory system thereby increasing the rate at which glucose is removed from the circulatory system. The insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Application
    Filed: June 18, 2002
    Publication date: October 31, 2002
    Inventors: Igor Gonda, Reid M. Rubsamen
  • Publication number: 20020124852
    Abstract: Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.
    Type: Application
    Filed: May 3, 2001
    Publication date: September 12, 2002
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
  • Patent number: 6431167
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: August 13, 2002
    Assignee: Aradigm Corporation
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
  • Patent number: 6431166
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: August 13, 2002
    Assignee: Aradigm Corporation
    Inventors: Igor Gonda, Reid M Rubsamen, Stephen J. Farr
  • Patent number: 6427681
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: August 6, 2002
    Assignee: Aradigm Corporation
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
  • Patent number: 6428769
    Abstract: The libido of adult human female patients is increased by the intrapulmonary delivery of testosterone. A formulation of testosterone is aerosolized and inhaled into a patient's lungs where particles of testosterone deposits on lung tissue and then enter the patient's circulatory system. The patient's testosterone level is enhanced well above baseline levels for a short period and subsides to baseline levels with normal metabolism thereby providing desired short term effects on enhanced libido without undesirable effects of long term enhanced testosterone levels. Additional formulations are provided including formulations for aerosolized delivery of sildenafil citrate which are delivered to male or female patients.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: August 6, 2002
    Assignees: Aradigm Corporation
    Inventors: Reid M. Rubsamen, Robert Cole
  • Patent number: 6408854
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by a method whereby an aerosolized insulin formulation is delivered to a patient's lungs and the rate at which the insulin is absorbed into the blood is increased by the use of an inhale-exhale breathing maneuver. Particles of insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The rate of absorption is enhanced by instructing the patient to inhale maximally and thereafter exhale maximally. This maneuver causes a spike in the rate at which insulin enters the circulatory system thereby increasing the rate at which glucose is removed from the circulatory system. The insulinmay be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: June 25, 2002
    Assignee: Aradigm Corporation
    Inventors: Igor Gonda, Reid M. Rubsamen
  • Publication number: 20020059932
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Application
    Filed: June 21, 2001
    Publication date: May 23, 2002
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr